Department of Anesthesiology
Author Title Type [ Year(Desc)]
Filters: Author is Savarese, John J  [Clear All Filters]
2003
Suzuki T, Lien CA, Belmont MR, Tjan J, Savarese JJ.  2003.  Edrophonium effectively antagonizes neuromuscular block at the laryngeal adductors induced by rapacuronium, rocuronium and cisatracurium, but not mivacurium.. Can J Anaesth. 50(9):879-85.
Boros EE, Samano V, Ray JA, Thompson JB, Jung DK, Kaldor I, Koble CS, Martin MT, Styles VL, Mook RA et al..  2003.  Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys.. J Med Chem. 46(12):2502-15.
2004
Heerdt PM, Kang R, The' A, Hashim M, Mook RJ, Savarese JJ.  2004.  Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs.. Anesthesiology. 100(4):846-51.
Belmont MR, Lien CA, Tjan J, Bradley E, Stein B, Patel SS, Savarese JJ.  2004.  Clinical pharmacology of GW280430A in humans.. Anesthesiology. 100(4):768-73.
Savarese JJ, Belmont MR, Hashim MA, Mook RA, Boros EE, Samano V, Patel SS, Feldman PL, Schultz J-AI, McNulty M et al..  2004.  Preclinical pharmacology of GW280430A (AV430A) in the rhesus monkey and in the cat: a comparison with mivacurium.. Anesthesiology. 100(4):835-45.
2009
Lien CA, Savard P, Belmont M, Sunaga H, Savarese JJ.  2009.  Fumarates: unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine.. J Crit Care. 24(1):50-7.
2010
Sunaga H, Malhotra JK, Yoon E, Savarese JJ, Heerdt PM.  2010.  Cysteine reversal of the novel neuromuscular blocking drug CW002 in dogs: pharmacodynamics, acute cardiovascular effects, and preliminary toxicology.. Anesthesiology. 112(4):900-9.
Sunaga H, Zhang Y, Savarese JJ, Emala CW.  2010.  Gantacurium and CW002 do not potentiate muscarinic receptor-mediated airway smooth muscle constriction in guinea pigs.. Anesthesiology. 112(4):892-9.
Heerdt PM, Malhotra JK, Pan BY, Sunaga H, Savarese JJ.  2010.  Pharmacodynamics and cardiopulmonary side effects of CW002, a cysteine-reversible neuromuscular blocking drug in dogs.. Anesthesiology. 112(4):910-6.
Savarese JJ, McGilvra JD, Sunaga H, Belmont MR, Van Ornum SG, Savard PM, Heerdt PM.  2010.  Rapid chemical antagonism of neuromuscular blockade by L-cysteine adduction to and inactivation of the olefinic (double-bonded) isoquinolinium diester compounds gantacurium (AV430A), CW 002, and CW 011.. Anesthesiology. 113(1):58-73.
2011
Heerdt PM, Wagner CL, DeMais M, Savarese JJ.  2011.  Noninvasive cardiac output monitoring with bioreactance as an alternative to invasive instrumentation for preclinical drug evaluation in beagles.. J Pharmacol Toxicol Methods. 64(2):111-8.
2015
Heerdt PM, Sunaga H, Savarese JJ.  2015.  Novel neuromuscular blocking drugs and antagonists.. Curr Opin Anaesthesiol. 28(4):403-10.
2016
Heerdt PM, Sunaga H, Owen JS, Murrell MT, Malhotra JK, Godfrey D, Steinkamp M, Savard P, Savarese JJ, Lien CA.  2016.  Dose-response and Cardiopulmonary Side Effects of the Novel Neuromuscular-blocking Drug CW002 in Man.. Anesthesiology. 125(6):1136-1143.
Sunaga H, Savarese JJ, McGilvra JD, Heerdt PM, Belmont MR, Van Ornum SG, Murrell MT, Malhotra JK, Savard PM, Jeannotte E et al..  2016.  Preclinical Pharmacology of CW002: A Nondepolarizing Neuromuscular Blocking Drug of Intermediate Duration, Degraded and Antagonized by l-cysteine-Additional Studies of Safety and Efficacy in the Anesthetized Rhesus Monkey and Cat.. Anesthesiology. 125(4):732-743.
2018
Kaullen JD, Owen JS, Brouwer KLR, Heerdt PM, Lien CA, Savarese JJ, Schmith VD.  2018.  Pharmacokinetic/Pharmacodynamic Model of CW002, an Investigational Intermediate Neuromuscular Blocking Agent, in Healthy Volunteers.. Anesthesiology. 128(6):1107-1116.
Savarese JJ, Sunaga H, McGilvra JD, Belmont MR, Murrell MT, Jeannotte E, Cooke FE, Wastila WB, Heerdt PM.  2018.  Preclinical Pharmacology in the Rhesus Monkey of CW 1759-50, a New Ultra-short Acting Nondepolarizing Neuromuscular Blocking Agent, Degraded and Antagonized by L-Cysteine.. Anesthesiology. 129(5):970-988.